<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>TAUROLIDINE - Research Report</title>
    <meta name="description" content="Comprehensive naturopathic research report for TAUROLIDINE">
    <style>

    * {
        box-sizing: border-box;
    }

    body {
        font-family: 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
        font-size: 16px;
        line-height: 1.6;
        margin: 0;
        padding: 0;
        background-color: #f8f9fa;
        color: #212529;
    }

    .container {
        max-width: 1200px;
        margin: 0 auto;
        padding: 20px;
        background-color: white;
        box-shadow: 0 0 10px rgba(0,0,0,0.1);
    }

    .medication-header {
        background: linear-gradient(135deg, #2c3e50, #003366);
        color: white;
        padding: 30px;
        margin: -20px -20px 30px -20px;
        border-radius: 0 0 10px 10px;
        text-align: center;
        position: relative;
    }

    .medication-header h1 {
        margin: 0 0 15px 0;
        font-size: 2.5em;
        font-weight: 600;
        text-shadow: 0 2px 4px rgba(0,0,0,0.3);
    }

    .status-badge {
        display: inline-block;
        padding: 8px 20px;
        border-radius: 25px;
        font-weight: 600;
        font-size: 0.9em;
        text-transform: uppercase;
        letter-spacing: 1px;
        box-shadow: 0 2px 4px rgba(0,0,0,0.2);
    }

    .status-allowed { background-color: #28a745; color: white; }
    .status-not-allowed { background-color: #dc3545; color: white; }
    .status-modernization { background-color: #fd7e14; color: white; }
    .status-topical { background-color: #20c997; color: white; }
    .status-review { background-color: #ffc107; color: #212529; }
    .status-not-applicable { background-color: #6c757d; color: white; }
    .status-unknown { background-color: #adb5bd; color: white; }

    .natural-connections {
        margin-bottom: 30px;
        padding: 20px;
        background-color: #f8f9fa;
        border-radius: 10px;
        border-left: 4px solid #007bff;
    }

    .natural-connections h2 {
        margin: 0 0 15px 0;
        font-size: 1.4em;
        color: #2c3e50;
    }

    .connection-tags {
        display: flex;
        flex-wrap: wrap;
        gap: 8px;
    }

    .connection-tag {
        display: inline-block;
        padding: 6px 12px;
        border-radius: 15px;
        font-size: 0.85em;
        font-weight: 500;
        color: white;
        white-space: nowrap;
    }

    .tag-direct { background-color: #0d6832; }
    .tag-semi-synthetic { background-color: #198754; }
    .tag-structural { background-color: #0d6efd; }
    .tag-endogenous { background-color: #6610f2; }
    .tag-biosynthetic { background-color: #6f42c1; }
    .tag-pathways { background-color: #0dcaf0; color: #212529; }
    .tag-processes { background-color: #3dd5f3; color: #212529; }

    .report-content {
        line-height: 1.7;
    }

    .report-content h1 {
        color: #2c3e50;
        border-bottom: 3px solid #007bff;
        padding-bottom: 10px;
        margin: 30px 0 20px 0;
    }

    .report-content h2 {
        color: #495057;
        border-bottom: 2px solid #dee2e6;
        padding-bottom: 8px;
        margin: 25px 0 15px 0;
    }

    .report-content h3 {
        color: #6c757d;
        margin: 20px 0 10px 0;
    }

    .report-content p {
        margin-bottom: 15px;
        text-align: justify;
    }

    .checkbox {
        font-weight: bold;
        margin-right: 5px;
    }

    .checkbox.checked { color: #28a745; }
    .checkbox.unchecked { color: #6c757d; }

    .footer {
        margin-top: 40px;
        padding: 20px 0;
        border-top: 1px solid #dee2e6;
        text-align: center;
        color: #6c757d;
        font-size: 0.9em;
    }

    .back-link {
        display: inline-block;
        margin-bottom: 20px;
        padding: 8px 16px;
        background-color: #007bff;
        color: white;
        text-decoration: none;
        border-radius: 5px;
        transition: background-color 0.3s;
    }

    .back-link:hover {
        background-color: #0056b3;
        text-decoration: none;
    }

    @media (max-width: 768px) {
        .container {
            padding: 15px;
            margin: 10px;
        }
        .medication-header {
            margin: -15px -15px 20px -15px;
            padding: 20px;
        }
        .medication-header h1 {
            font-size: 2em;
        }
        .connection-tags {
            justify-content: center;
        }
    }

    @media print {
        .back-link { display: none; }
        .container { box-shadow: none; }
        .medication-header {
            background: #2c3e50 !important;
            -webkit-print-color-adjust: exact;
        }
    }

    </style>
</head>
<body>
    <div class="container">
        <a href="index.html" class="back-link">← Back to Index</a>

        <header class="medication-header">
            <h1>TAUROLIDINE</h1>
            <div class="status-badge status-not-allowed">
                NOT_ALLOWED
            </div>
        </header>

        <section class="natural-connections">
            <h2>Natural Connections</h2>
            <div class="connection-tags">
                <span class="connection-tag tag-direct">Direct Natural</span>
<span class="connection-tag tag-semi-synthetic">Semi-Synthetic</span>
<span class="connection-tag tag-structural">Structural Analog</span>
<span class="connection-tag tag-pathways">Works Natural Pathways</span>
<span class="connection-tag tag-processes">Facilitates Natural Processes</span>
            </div>
        </section>

        <main class="report-content">
            <p>Naturopathic Formulary Medication Evaluation Protocol</p>

<p># Objective: Comprehensive assessment of natural derivation and therapeutic alignment For <strong>TAUROLIDINE</strong>:</p>

<strong>Evidence Categories Present:</strong>

<span class="checkbox checked">✓</span> Direct natural source <span class="checkbox checked">✓</span> Semi-synthetic from natural precursor <span class="checkbox checked">✓</span> Structural analog of natural compound <span class="checkbox unchecked">☐</span> Endogenous compound or replacement <span class="checkbox unchecked">☐</span> Biosynthetic/fermentation product <span class="checkbox checked">✓</span> Works through natural pathways/receptors <span class="checkbox checked">✓</span> Facilitates natural physiological processes <span class="checkbox unchecked">☐</span> No identified natural connection

<h2>1. NATURAL DERIVATION ASSESSMENT</h2>

<p>### <h3>Source Investigation</h3> TAUROLIDINE is derived from natural sources. Taurolidine is a synthetic derivative of the naturally occurring amino acid taurine. Taurine is found abundantly in mammalian tissues, particularly in the heart, brain, retina, and skeletal muscle. It is also present in bile salts and is naturally synthesized in the human body from cysteine and methionine. The compound was developed through pharmaceutical research. derivation from taurine, a naturally occurring and physiologically important amino acid. The compound maintains structural similarity to its natural precursor while providing enhanced therapeutic properties. It integrates well with natural biological systems, utilizing endogenous pathways for metabolism and immune modulation, making it highly compatible with naturopathic therapeutic approaches. <p><strong><strong>Relevant Citations:</strong></strong></p></p>

<ol>

<li>DrugBank Online. &quot;Taurolidine.&quot; DrugBank Accession Number DB11596. University of Alberta, 2024. https://go.drugbank.com/drugs/DB11596 2. Torres-Viera C, Thauvin-Eliopoulos C, Souli M, DeGirolami P, Farris MG, Wennersten CB, Sofia RD, Eliopoulos GM. &quot;Activities of taurolidine in vitro and in experimental enterococcal endocarditis.&quot; Antimicrobial Agents and Chemotherapy. 2000;44(6):1720-1724.</li>

<li>Jacobi CA, Menenakos C, Braumann C. &quot;Taurolidine--a new drug with anti-tumor and anti-angiogenic effects.&quot; Anti-Cancer Drugs. 2005;16(9):917-921.</li>

<li>Braumann C, Tangermann J, Jacobi CA, Müller JM, Dubiel W. &quot;Novel anti-angiogenic properties of the anti-infective agent taurolidine.&quot; Journal of Antimicrobial Chemotherapy. 2006;57(5):914-920.</li>

<li>European Medicines Agency. &quot;Assessment Report for Taurolock (taurolidine/citrate).&quot; Committee for Medicinal Products for Human Use. EMA/CHMP/625418/2013, 24 October 2013.</li>

<li>Huxtable RJ. &quot;Physiological actions of taurine.&quot; Physiological Reviews. 1992;72(1):101-163.</li>

<li>Schaffer SW, Jong CJ, Ramila KC, Azuma J. &quot;Physiological roles of taurine in heart and muscle.&quot; Journal of Biomedical Science. 2010;17 Suppl 1:S2.</li>

<li>PubChem. &quot;Taurolidine.&quot; PubChem Compound ID: 5381. National Center for Biotechnology Information, 2024.</li>

<li>Lock JF, Reinhold T, Malinowski M, Weimann A, Neuhaus P, Stockmann M. &quot;The costs of postoperative liver transplant complications.&quot; Transplantation Proceedings. 2010;42(6):2191-2195.</li>

</ol>
        </main>

        <footer class="footer">
            <p>Generated on September 24, 2025 at 07:19 AM</p>
        </footer>
    </div>
</body>
</html>